

PATIENT INFORMATION
PATIENT NAME: _____ **PHONE:** _____

DATE OF BIRTH: _____ **SEX:** M F **HEIGHT:** _____ **WEIGHT:** _____ LBS KG

ALLERGIES: _____ **PREFERRED CLINIC:** _____

REFERRAL STATUS: NEW REFERRAL ORDER CHANGE ORDER RENEWAL

DIAGNOSIS & CLINICAL DOCUMENTATION

- | | |
|--|--|
| <input type="checkbox"/> D59.30 Hemolytic Uremic Syndrome (aHUS) | <input type="checkbox"/> G70.00 Myasthenia Gravis without acute exacerbation |
| <input type="checkbox"/> D59.5 Paroxysmal nocturnal hemoglobinuria (PNH) | <input type="checkbox"/> G70.01 Myasthenia Gravis with acute exacerbation |
| <input type="checkbox"/> G36.0 Neuromyelitis optica (NMOSD) | |
| <input type="checkbox"/> ICD-10 CODE: _____ DESCRIPTION: _____ | |

REQUIRED DOCUMENTATION

- | | | | | | |
|--|--|---|---|--|--|
| <input type="checkbox"/> Insurance Information | <input type="checkbox"/> List of Medications | <input type="checkbox"/> Tried & failed Therapies | <input type="checkbox"/> Most recent History & Physical | <input type="checkbox"/> Anti-AChR or Anti-AQP4 Status | <input type="checkbox"/> Meningococcal vaccine records |
|--|--|---|---|--|--|

MEDICATION ORDER
***For Patients Weighing 40 kg to 59 kg**

- LOADING:** Ultomiris® (ravulizumab) 2400 mg IV per protocol at week 0
- MAINTENANCE:** Ultomiris® (ravulizumab) 3000 mg IV per protocol every 8 weeks (starting 2 weeks after loading dose)

***For Patients Weighing 60 kg to 100 kg**

- LOADING:** Ultomiris® (ravulizumab) 2700 mg IV per protocol at week 0
- MAINTENANCE:** Ultomiris® (ravulizumab) 3300 mg IV per protocol every 8 weeks (starting 2 weeks after loading dose)

***For Patients Weighing GREATER Than 100 kg**

- LOADING:** Ultomiris® (ravulizumab) 3000 mg IV per protocol at week 0
- MAINTENANCE:** Ultomiris® (ravulizumab) 3600 mg IV per protocol every 8 weeks (starting 2 weeks after loading dose)
- OTHER:** _____

*Flush with 30 ml NS after each infusion

 REFILL X 12 MONTHS UNLESS OTHERWISE NOTED HERE: _____

Patient to be observed for 60 minutes following each infusion. Administer per protocol. In the event of an adverse reaction occurring in the infusion clinic, utilize the Immersiv Health adverse reaction protocol.
PRESCRIBER INFORMATION
PROVIDER NAME: _____ **NPI #:** _____

EMAIL: _____ **PHONE:** _____ **FAX:** _____

ADDRESS (INCLUDE CITY, STATE, ZIP): _____

SUPERVISING PHYSICIAN: _____ **CONTACT NAME:** _____
(IF APPLICABLE)
SIGNATURE: _____ **DATE:** _____
(NO STAMPS)

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN